You're watching...
Ariad Pharmaceuticals CEO Dr. Harvey Berger on the company’s new lung-cancer drug.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
It's been a great.
Couple years actually from my next business that we -- profiling -- a new miracle cancer drug be available on the market as early as next year first quarter.
Area pharmaceuticals drugs are on the fast track to FDA approval the stock has -- on a fast -- as well up more than a 140%.
Year over year doctor Harvey Berger is ARIAD Pharmaceuticals founder -- CEO and passionate flag -- -- joining us explicitly.
-- Q1 but also just as important next Prague.
Which is a lung cancer drug that as of right now doesn't have a name it's 113 rights that's.
This is a on a new medicine for our patients -- lung cancer gets to try to put this into perspective lung cancer is still be number one.
Cause of cancer death in men and women.
We've made -- I don't want number one absolutely in terms of death.
Both in men and women more than breast cancer although they're more cases of breast cancer.
We've done less in lung cancer.
And now physicians cancer doctors are really looking at lung cancer.
More from the genetic point of view and not saying are you -- smoker or not but what sort of genetics the you have in that cancer itself.
And then personalizing.
That therapy like our new drug 113 for certain genetic profiles of.
One -- OK so this is for non small cell this is -- are tumor right.
But what is it about 113 that shows such promise to the point where the FDA is going too fast track it which means it skips a step.
Well we don't know exactly how the FDA yes will you know look at the overall process for 113 but medical community is really excited about.
The results we present -- results couple weeks facts about two weeks ago when Europe.
The first clinical data.
Take for example one of the genetic -- is called a LK it -- subset of these genetic forms of lung cancer in virtually every patient.
That we treated whether they failed the other drugs that are available or whether -- we're at the beginning of treatment had a response to tumors shrank.
Patients felt better and even if they had tumor that it's spread to the brain which happens in about half of lung cancer patients it went away.
OK so -- fire -- somebody who has lung cancer and I've been trying other things I'm thinking.
Doctor Parker struck is my last great hope which brings me to the drugs that may very well be fat it's fast track now and that meant that right that is for leukemia types of drugs is -- the tragic drugs I go through the blood.
Tell me about when that will be available to patients who other therapies have already failed so this is their last -- We'll -- -- -- drug for chronic my would leukemia form of blood cancer.
It's working its way through final steps of the regulatory review here in the US it's also being reviewed in Europe.
We expect connected to be available to cancer patients by the first quarter of next here perhaps a bit earlier but certainly over the coming months it should be developed.
Well doctor -- and I know you as the doctor very close and and passionate and and very emotional about these things but we're hearing from analysts that this could be a one point five billion dollar a year in revenue drugs that.
Easily.
Clears the wine.
As a Blockbuster company.
Well you know what we've learned is that drugs met cancer medicines and that really work that make a difference in the lives of cancer patients and can be used.
Over prolonged periods of time whether leukemia or maybe lung cancer that's what drives first value for patients but then importantly value -- their current from doctor saying when am -- going to be able to get and that meant to -- look at absolutely we we supply the medicine through.
Expanded access through compassionate use around the world something like I think twenty countries.
We -- physicians today if they need and -- that they can get it for their leukemia patients the first time you were with us.
Back in July of 2011 since then this stock folks up 96%.
It has far outpace the Dow Jones Biotech index which is up 37%.
A pretty much for the same amount of time.
Quickly tell me.
A third drug court hearing you guys have a third broken apart -- We certainly it have both -- third and a fourth drug behind an active and 113 we view these these cries.
Well for other types of cancer of the same concept.
Overcoming resistance cancers that are really hard to treat we haven't said which one yet but you know where applying that same methods that we use.
-- developing other drugs and what I think distinguishes area -- it and separates it from the big pharma companies is that -- -- repeatedly able to take this method these techniques.
And discover -- -- hand you have to partner with a -- pharma company intent for distribution absolutely now we're doing all of that help partnership no partnerships now or in the future.
C could do it on your on you we're going to -- our.
One point five billion for cannot have at least at least okay -- we have it right here doctor you know when we use the word miracle like get I get annoyed because the miracle is.
Brilliant doctors who work at area and you yourself so -- wish -- -- -- of luck.
Giving hope to patients who have run out of hope and absolutely that's why we do this doctor Harvey Parker area pharmaceutical founder chairman and CEO we brought him here.
In July of 2011.
Ad deal listen okay ticker symbol AR IA will be watching so closely wishing them luck.
